Fewer Patients With CLL/SLL Switch From Zanubrutinib to Another BTKi
A retrospective switching study recently presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting suggests a potential advantage for zanubrutinib over other Bruton tyrosine kinase inhibitors ...
Phase II CAPTIVATE Study: The 5.5-Year Update
Ibr+Ven, an all-oral, once-daily, chemotherapy-free treatment, leverages the compounds’ ability to work synergistically through distinct and complementary modes of action to eliminate resting and dividing CLL subpopulations ...
AI Electrocardiography Predicts Atrial Fibrillation Risk in Patients with CLL
Patients with newly diagnosed chronic lymphocytic leukemia (CLL) have an estimated 1% risk per year of atrial fibrillation (AF) incidence ...
In the Long Run, Ibrutinib Brings Disease Control, but Cardiac Risks, in Older Patients With Untreated CLL
Older patients with chronic lymphocytic leukemia (CLL) who were previously untreated continue to show durable responses with Bruton tyrosine kinase (BTK) inhibitor ibrutinib-based therapies ...
MRD-Directed Combo of Ibrutinib Plus Venetoclax Improves PFS, OS Among Patients With Treatment-Naïve CLL
Findings from the U.K.-based phase III FLAIR trial, presented at the 65th ASH Annual Meeting and Exposition, provide data on the efficacy of the combination of venetoclax plus ibrutinib for patients ...
Pirtobrutinib Effective in CLL/SLL After cBTKi, Analysis Shows
Patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) who were treated with the non-covalent Bruton’s tyrosine kinase inhibitor (ncBTKi) pirtobrutinib after treatment with a covalent BTKi ...
PI3K Inhibitors: A Series of Unfortunate Events
PI3K inhibitors were once a promising class of drugs for CLL. Now, their stock has fallen in favor of newer therapies ...
Global Real-World Patient Survey Identifies Need for Support, Patient Education in CLL
A survey of 377 patients with chronic lymphocytic leukemia (CLL) around the world has shown the gaps in knowledge of disease risk stratification and patients’ susceptibility to infections such as SARS-CoV-2 ...
Prognostic Testing Underused for Patients with CLL/SLL
An analysis of the informCLL registry has revealed that, although the selection of chronic lymphocytic leukemia (CLL) treatment has shifted over time to newer targeted agents, one-third of patients continue to receive chemoimmunotherapy ...
Flow Cytometry Identified as Less Expensive Method to Learn IGHV Status in CLL
Flow cytometry could be used to determine the mutation status of immunoglobulin heavy chain variable (IGHV) gene in chronic lymphocytic leukemia ...
